Clariant launches medical polymer compounds resistant to hydrolytic degradation
- Testing shows dramatic improvement in critical properties
- Marketed under MEVOPUR® brand name, compounds are ideal for medical catheter applications
- New resins featured at MD&M West 2020, booth 2351
Muttenz, February 11, 2020 – Working with a leading medical device manufacturer, Clariant Plastics & Coatings Healthcare Polymer Solutions has completed development and testing of new polymer materials specially formulated to resist degradation caused by exposure to high humidity and temperature. The new technology is especially important in resins that incorporate high loadings of radiopaque metals because these fillers are known to exacerbate the degradation effect.
The new compounds, marketed under the MEVOPUR brand name covering Clariant’s ‘medical grade’ materials, are expected to be especially useful in applications like medical catheters. They are among several innovations being presented at MD&M West 2020, held in Anaheim, CA, February 11-13. Clariant Healthcare Polymer Solutions is exhibiting in booth 2351.
Catheters are typically made of relatively soft, flexible materials like polyether block amides (PEBA) or certain thermoplastic polyurethanes (TPU). These materials commonly contain metallic fillers like tungsten or tungsten carbide so that doctors and technicians can see the exact position of the catheter under X-ray fluoroscopy. “The problem is,” explains Steve Duckworth, Global Head of Marketing & Business Development, “when these devices are exposed to heat and humidity over time, the polymer chains responsible for developing critical physical and mechanical properties become broken and the functionality of the device – and patient safety – may be seriously compromised.” According to Duckworth, these hydrolysis effects can occur even with very small quantities of moisture trapped on the surface of the polymer, filler ingredients, or on the pellets of the compound.
The Clariant solution is a combination of proprietary processing techniques and additives that, together, help to make the polymer resistant to hydrolytic degradation. Accelerated aging tests conducted on both extruded tubing and injection-molded test samples show significant improvement in resistance compared to unmodified materials.
One of the early indications of chain breakage (scission) is an increased melt flow index (MFI), or reduction in viscosity, as the chains become shorter. The MFI of a standard 74% tungsten-filled PEBA Shore 35D compound was compared to an otherwise equivalent MEVOPUR modified compound over a 26-week period. In just the first few weeks, there was a significant increase in melt fluidity of the standard resin, and after the 4th week, the MFI was no longer measurable. Over the same period, the modified MEVOPUR compound showed almost no change. The observed difference was even greater during testing when tungsten-carbide-filled materials were used.
When the same materials were molded into tensile-test bars and measured for tensile strength and elongation, the unmodified samples saw reduction of 20 to 25% in these critical properties over the 26-week test period, while the MEVOPUR samples remained near 100%. In further mechanical-properties testing, the difference in results for tungsten-carbide-filled materials was much more pronounced.
“The final quality and reliability of catheter components relies on the stability and predictability of polymer material properties over a wide range of conditions,” Duckworth says. “Our testing on the new MEVOPUR radiopaque compounds shows the risk of polymer degradation from hydrolysis can be significantly reduced so predictability can be restored. This also demonstrates the importance of long-term collaboration between the device manufacturer and a materials supplier like Clariant.
Clariant manufactures MEVOPUR concentrates and compounds at its EN:ISO13485-2016 certified facility in Lewiston Maine, part of a global network of ISO13485 facilities that also includes sites in Europe and Asia. The dedicated expertise of the Clariant’s Healthcare Polymer Solutions team has developed products from PE to PEEK using USP Class VI, ISO10993 pre-tested ingredients. The MEVOPUR portfolio has included PEBA, TPU, PA12, along with various radiopaque fillers, for more than 10 years. Fluoropolymers were recently added to the portfolio.
MEVOPUR® IS A TRADEMARK OF CLARIANT REGISTERED IN MANY COUNTRIES.
This information corresponds to the present state of our knowledge and is intended as a general description of our products and their possible applications. Clariant makes no warranties, express or implied, as to the information’s accuracy, adequacy, sufficiency or freedom from defect and assumes no liability in connection with any use of this information. Any user of this product is responsible for determining the suitability of Clariant’s products for its particular application.<br /> <br /> * Nothing included in this information waives any of Clariant’s General Terms and Conditions of Sale, which control unless it agrees otherwise in writing. Any existing intellectual/industrial property rights must be observed. Due to possible changes in our products and applicable national and international regulations and laws, the status of our products could change. Material Safety Data Sheets providing safety precautions, that should be observed when handling or storing Clariant products, are available upon request and are provided in compliance with applicable law. You should obtain and review the applicable Material Safety Data Sheet information before handling any of these products. For additional information, please contact Clariant.<br /> <br /> * For sales to customers located within the United States and Canada the following applies in addition: No express or implied warranty is made of the merchantability, suitability, fitness for a particular purpose or otherwise of any product or service.<br /> <br /> © Trademark of Clariant registered in many countries.<br /> ® 2019 Clariant International Ltd